TECHNICAL PROCEDURE MANUAL
Creatinine Plus Roche/Hitachi 911
Test Name:
Instrument:
Manufacturer:
Creatinine Plus
Roche/Hitachi 911
Roche Diagnostics
Effective date for this procedure: January 3, 2004__________________________________
1 of 7
TECHNICAL PROCEDURE MANUAL
Creatinine Plus Roche/Hitachi 911
Intended Use
Enzymatic in vitro assay for the direct quantitative determination of creatinine in human serum, plasma and
urine using clinical chemistry analyzers.
Please refer to your Package Insert or Operator's Manual for areas not completed.
Summary
Creatinine is produced endogenously from creatine and creatine phosphate as a result of muscle metabolic
processes. It is excreted by glomerular filtration during normal renal function. Creatinine assays are
conducted for diagnostic purposes, for therapeutic monitoring of acute and chronic renal diseases, and for
monitoring kidney dialysis. The urinary creatinine concentration can also be used as a reference parameter
for analyte excretion (albumin, α-amylase).
Numerous methods have been described for determining creatinine, including the Jaffé alkaline picrate
method in various modifications, as well as an enzymatic test which involves measuring ammonia after
cleavage of creatinine by creatinine iminohydrolase.
The enzymatic method is based on the established determination of sarcosine after conversion of creatinine
with the aid of creatininase, creatinase, and sarcosine oxidase. The liberated hydrogen peroxide is
measured via a modified Trinder reaction. Optimization of the buffer system and the colorimetric indicator
enables the creatinine concentration to be quantified both precisely and specifically. Moreover, the
results of this method correlate with those obtained by HPLC.
Principle
Enzymatic colorimetric assay
 Sample and addition of R1 (buffer/enzymes/HTIB) – Endogenous creatine is metabolized and lipemic
sera are cleared of turbidity.
 Addition of R2 (buffer/enzymes/4-aminophenazone) and start of reaction:
creatinine + H2O
creatine + H2O
creatininase
creatinase
sarcosine + H2O + O2
creatinine Creatininase hydrolyzes creatinine to creatine.
sarcosine + urea Creatininase hydrolyzes creatinine to sarcosine.
sarcosine oxidase
glycine + HCHO + H2O2
Sarcosine is converted to glycine, formaldehyde, and hydrogen peroxide in the presence of oxygen by the
action of sarcosine oxidase.
H2 O2 +4-aminophenazone +HTIB
peroxidase
quinone imine chromogen +H2O +HI
The liberated hydrogen peroxide reacts with 4-aminophenazone and HTIB to form a quinone imine
chromogen. The reaction is catalyzed by peroxidase. The color intensity is directly proportional to the
concentration of creatinine present and can be measured photometrically.
Specimen Collection and Handling
Universal Precautions apply.
Collect serum using standard sampling tubes
Plasma: The only acceptable anticoagulants are Li-heparin or Na-EDTA
Stability: 7 days at 2 –8 °C, Freeze for long-term storage.
Urine
Stability: 4 days at 2 –8 °C, Freeze for long-term storage. Collect urine without using preservatives.
Roche/Hitachi analyzers with automatic dilution
2 of 7
TECHNICAL PROCEDURE MANUAL
Creatinine Plus Roche/Hitachi 911
Urine samples are diluted 1 +10 with distilled or deionized water, or 0.9%NaCl. This dilution is taken into
account when the results are calculated.
3 of 7
TECHNICAL PROCEDURE MANUAL
Creatinine Plus Roche/Hitachi 911
Roche/Hitachi analyzers without dilution
Dilute urine samples manually 1 +10 with distilled or deionized water, or 0.9%NaCl. Multiply the result
by 11.
Samples containing precipitate must be centrifuged before performing the assay.
If testing cannot occur immediately, laboratory protocol is: Store at -70ºC_________________________
Materials and Equipment Required
Test Instrument: Roche/Hitachi 911
Materials Provided:
Working solutions as described in the package insert.
Additional Materials Required (but not provided):



Calibrators and controls as indicated within the Calibration and Quality sections of this document.
0.9% NaCl
General laboratory equipment
Reagents
R1
R2
TAPS buffer
30 mmol/l, pH 8.1;creatinase ≥ 20 kU/l (microorganisms); sarcosine oxidase ≥ 8 kU/l
(microorganisms); ascorbate oxidase ≥ 2 kU/l (microorganisms); HTIB: 1.2 g/l; detergents;
preservative
TAPS buffer
50 mmol/l,pH 8.0; creatininase ≥ 30 kU/l (microorganisms); peroxidase ≥ 1 kU/l (horseradish);
4-aminophen-azone:0.4 g/l; potassium hexacyanoferrate (II):60 mg/l; detergent;
preservative
Storage and Stability
Unopened kit components: Up to the expiration date at 2-8 °C
R1: 28 days opened and refrigerated on the analyzer.
R2: 28 days opened and refrigerated on the analyzer.
Supplier(s) for the above materials: Roche___________________________________________________
____________
Phone number of the supplier(s):
800-428-2336_____________________________________________
Calibration
This test has been calibrated against HPLC.
S1: 0.9% NaCl or distilled/deionized water
S2: C.f.a.s. (Calibrator for automated systems), Cat. No. 10759350 (USA #759350)
Calibration frequency – re-calibration is recommended.
 as blank calibration every 28 days
 as 2 point calibration after reagent lot change.
 as 2 point calibration as required following quality control procedures.
Calibration verification: Not necessary.
Refer to the appropriate calibration section of your Operator's Manual and/or the Package Insert for specific
calibration instructions.
4 of 7
TECHNICAL PROCEDURE MANUAL
Creatinine Plus Roche/Hitachi 911
Quality Control
Serum/plasma
For quality control, use Precinorm U, Precinorm U plus, Precipath U, Precipath U plus or other suitable
control material.
Urine
For quality control use Precinorm Albumin, Precipath Albumin or other suitable control material. The
control intervals and limits should be adapted to the individual laboratory requirements. Values obtained
should fall within established limits. Each laboratory should establish corrective measures to be taken if
values fall outside the limits.
If controls do not recover within the specified limits, take the following corrective action.
_See QA/QC Manuel for details_of corrective action________________________________________________
_____________________________________________________________________________________________
Refer to the appropriate value sheets/Package Insert for additional information.
Preparation of Working Solutions
R1: Ready for use
R2: Ready for use
Assay
For optimal performance of this assay follow the directions given for the analyzer used. Refer to the
appropriate operator’s manual and/or the Instrument Settings section of this insert for analyzer-specific
assay instructions.
The performance of applications not validated by Roche is not warranted and must be defined by the user.
Interpretation: Reporting Results
Refer to the Package Insert for expected values:
Expected Values
_______________________________________________________________________________
_______________________________________________________________________________
Critical Values
_______________________________________________________________________________
_______________________________________________________________________________
Protocol to follow if critical value result is obtained:
_Alert physician or study coordinator and document in the “Alert Log”.___________________
_________________________________________________________________________________
5 of 7
TECHNICAL PROCEDURE MANUAL
Creatinine Plus Roche/Hitachi 911
Precautions and Warnings
For in vitro diagnostic use
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Limitations — Interference
Criterion: Recovery within ± 10% of initial values for creatinine concentrations of 1 mg/dl in serum and
100 mg/dl in urine.
Serum/Plasma
Icterus: No significant interference up to an I index of 25 (approximate conjugated and unconjugated
bilirubin concentration: 25 mg/dl or 428 µmol/l).
Hemolysis: No significant interference up to an H index of 1000 (approximate hemoglobin
concentration:1000 mg/dl or 621 µmol/l).
Lipemia (Intralipid):No significant interference up to an L index of 1000. There is a poor correlation
between the L index (corresponds to turbidity)and triglycerides concentration.
Ascorbic acid <300 mg/l does not interfere.
Calcium dobesilate (e.g. Dexium) gives falsely low recoveries from 5 mg/l. N-ethylglycine and DL-proline
at therapeutic concentrations give falsely high results. Cephalosporin antibiotics do not affect this
test. Of 15 additional commonly used drugs tested in vitro, none interfered with the assay.
Hemolyzed samples from neonates, infants or adults with HbF values ≥ 600 mg/dl interfere with the test.
In very rare cases monoclonal gammopathy can lead to incorrect results.
Urine
Icterus: No significant interference up to an approximate conjugated bilirubin concentration of 70 mg/dl
(1197 µmol/l).
Hemolysis: No significant interference up to an approximate hemoglobin concentration of 1000 mg/dl (621
µmol/l).
Ascorbic acid <300 mg/l,glucose <2000 mg/dl and urobilinogen <40 mg/dl do not interfere.
Calcium dobesilate (e.g. Dexium) and α-methyldopa give falsely low recoveries. Of 10 additional
commonly used drugs tested in vitro, none interfered with the assay.
Performance Characteristics
Refer to appropriate Package Insert.
Contacts:
Technical Support:
Roche Response Center® Customer Technical Support: 1.800.428.2336
Service:
Number to call for service: _Above___________________________
References
Creatinine Plus Package Insert
Roche Diagnostics Corporation
9115 Hague Rd.
Indianapolis, IN 46256
P/N 1935976001
6 of 7
TECHNICAL PROCEDURE MANUAL
Creatinine Plus Roche/Hitachi 911
Effective Date
Effective date for this procedure: January 3, 2004_____________________________
Author
Compiled by Roche Diagnostics Corporation
Revised by: Charlie Rhodes_________________________________________________
Schedule for Review (See QA/QC SOP Manuals for Signatures)
Last date revised: ____________________________________________
Date Reviewed:_____________ Approved:_______________________________
Date Reviewed:_____________ Approved:_______________________________
Date Reviewed:_____________ Approved:_______________________________
Date Reviewed:_____________ Approved:_______________________________
Date Reviewed:_____________ Approved:_______________________________
Date Reviewed:_____________ Approved:_______________________________
Date Reviewed:_____________ Approved:_______________________________
Date Reviewed:_____________ Approved:_______________________________
Date Reviewed:_____________ Approved:_______________________________
Date Reviewed:_____________ Approved:_______________________________
7 of 7